CHA
PMVP icon

Cooper/Haims Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Cooper/Haims Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.3K Buy
+39,021
New +$50.1K 0.02% 114

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Cooper/Haims Advisors's PMVP Position: Q2 2026 in Review

Cooper/Haims Advisors opened a new position in PMV Pharmaceuticals (PMVP) in Q2 2026: 39,021 shares worth $52.3K. The stake represents 0.02% of the portfolio and ranks #114 among its holdings.

64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Cooper/Haims Advisors held 39,021 shares of PMV Pharmaceuticals worth $52.3K as of Q2 2026.
  • PMV Pharmaceuticals was a new Cooper/Haims Advisors position in Q2 2026.
  • PMV Pharmaceuticals made up 0.02% of Cooper/Haims Advisors's portfolio in Q2 2026, its #114 holding.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Cooper/Haims Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.